Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-i axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 11206939_1 (GHMatters) P101885.AU.1 o co ItL LL C: C: CC) C) co0~ 0 U) F- 0 \J U) 0 0 0 ' ) 0 o) D CfO 0 IdlW 11911 (jeww)owflOA jowf.ljueipeo C/)FH ...

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-i axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 17503644_1 (GHMatters) P101885.AU.2 ...

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 1. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity.2. A method for treating or delaying progression of an immune related disease in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity.3. The method of claim 2 , wherein the immune related disease is associated with a T cell dysfunctional disorder.4. The method of claim 3 , wherein the T cell dysfunctional disorder is characterized by T cell exhaustion.5. The method of claim 2 , wherein the immune related disease is selected from the group consisting of unresolved acute infection claim 2 , chronic infection claim 2 , and tumor immunity.6. A method of treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that modulates CD226 expression and/or activity.7. A method for treating or delaying progression of an immune related disease in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that modulates CD226 expression and/or activity.8. The method of claim 7 , wherein the immune related disease is associated with a T cell dysfunctional disorder.9. The method of claim 8 , wherein the T cell dysfunctional disorder is characterized by T cell exhaustion.10. ...

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 1. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity.2. A method for treating or delaying progression of an immune related disease in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity.3. The method of claim 2 , wherein the immune related disease is associated with a T cell dysfunctional disorder.4. The method of claim 3 , wherein the T cell dysfunctional disorder is characterized by T cell exhaustion.5. The method of claim 2 , wherein the immune related disease is selected from the group consisting of unresolved acute infection claim 2 , chronic infection claim 2 , and tumor immunity.6. A method of treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that modulates CD226 expression and/or activity.7. A method for treating or delaying progression of an immune related disease in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an agent that modulates CD226 expression and/or activity.8. The method of claim 7 , wherein the immune related disease is associated with a T cell dysfunctional disorder.9. The method of claim 8 , wherein the T cell dysfunctional disorder is characterized by T cell exhaustion.10. ...

Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 1166.-. (canceled)167. A method of treating cancer in a human subject in need thereof , comprising administering to the human subject an effective amount of:a. an anti-PD-L1 antagonistic antibody; andb. an anti-TIGIT antagonistic antibody.168. The method of claim 167 , wherein the anti-TIGIT antagonistic antibody is a human antibody or a humanized antibody.169. The method of claim 167 , wherein the anti-TIGIT antagonistic antibody is a monoclonal antibody.170. The method of claim 167 , wherein the anti-TIGIT antagonistic antibody is a monoclonal humanized antibody.171. The method of claim 167 , wherein the anti-TIGIT antagonistic antibody is a monoclonal human antibody.172. The method of claim 167 , wherein the anti-TIGIT antagonistic antibody is an IgG antibody.173. The method of claim 172 , wherein the anti-TIGIT antagonistic antibody is an IgG-1 antibody.174. The method of claim 173 , wherein the anti-TIGIT antagonistic antibody is a monoclonal human IgG-1 antibody or a monoclonal humanized IgG-1 antibody.175. The method of claim 172 , wherein the anti-TIGIT antagonistic antibody is an IgG-4 antibody.176. The method of claim 175 , wherein the anti-TIGIT antagonistic antibody is a monoclonal human IgG-4 antibody or a monoclonal humanized IgG-4 antibody.177. The method of claim 167 , wherein the anti-PD-L1 antagonistic antibody comprises a heavy chain comprising a HVR-H1 sequence of GFTFSDSWTH (SEQ ID NO: 17) claim 167 , a HVR-H2 sequence of AWISPYGGSTYYADSVKG (SEQ ID NO: 18) claim 167 , and a HVR-H3 sequence of RHWPGGFDY (SEQ ID NO: 19); and a light chain comprising a HVR-L1 sequence of RASQDVSTAVA ( ...

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

METHOD OF CONDITIONALLY RETAINING A PROTEIN OF INTEREST IN THE ENDOPLASMIC RETICULUM

L'invention concerne un acide nucléique codant pour une protéine de fusion comprenant un domaine de rétention conditionnelle constitué d'un domaine FRB suivi d'un motif de rétention dans le réticulum endoplasmique. Les vecteurs d'expression et cellules transformées par de tels vecteurs font également partie de la présente invention. Sous un autre aspect, l'invention comprend également des méthodes de rétention conditionnelle dans le réticulum endoplasmique de protéine d'intérêt mettant en œuvre ces vecteurs ainsi que des kits ou trousse de réactifs comprenant de tels acides nucléiques ou vecteurs. The invention provides a nucleic acid encoding a fusion protein comprising a conditional retention domain consisting of a FRB domain followed by a retention pattern in the endoplasmic reticulum. Expression vectors and cells transformed with such vectors are also part of the present invention. In another aspect, the invention also includes methods for conditional retention in the endoplasmic reticulum of the protein of interest using these vectors as well as kits or kit of reagents comprising such nucleic acids or vectors.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-interleukin-33 antibodies and their uses.

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)). The invention provides antibodies to interleukin-33 (IL-33) and methods of making and using these, for example, for the treatment of IL-33-mediated disorders (eg, ocular disorders such as AMD (eg, geographic atrophy). (GA)).

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Anti-interleukin-33 antibodies and uses thereof

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)).  

Anticuerpos anti-interleucina-33 y usos de estos.

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)).

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Ｐｄ－１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法

【課題】がん又は慢性感染の治療のための腫瘍免疫原性の増加のような免疫原性の亢進が望まれる病態を治療する方法、並びにキットを提供する。【解決手段】個体におけるがんを治療し又はその進行を遅延させる方法において、有効量のＰＤ－１軸結合アンタゴニストとＴＩＧＩＴ発現及び／又は活性を減少させ又は阻害する薬剤とを個体に投与することを含む方法である。【選択図】図７Ａ－７Ｃ

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present disclosure describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for detection of IL-33 in biological samples.

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-i axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 17503644_1 (GHMatters) P101885.AU.2

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

The present invention describes combination treatment comprising a PD-i axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection. 17503644_1 (GHMatters) P101885.AU.2